Navigation Links
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Date:2/6/2009

CAMBRIDGE, Mass. and LONDON, Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS. New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects associated with this drug class. To date, IDX899 has demonstrated high potency with low milligram doses, a high barrier to drug resistance, favorable risk/benefit profile, and the convenience of once-a-day administration.

Under the terms of the agreement, GSK will assume all development responsibility and associated costs for IDX899, and Idenix will receive an upfront payment of $34 million and will be eligible to receive up to $416 million in development, regulatory and sales milestones. Furthermore, if IDX899 is successfully developed and commercialized, Idenix will receive double-digit, tiered worldwide royalties.

"GSK, with a well-established HIV franchise and substantial drug development experience, is the ideal collaborator to help maximize the potential of IDX899," said Jean-Pierre Sommadossi, Chief Executive Officer of Idenix. "For Idenix, the significant value created through the license of IDX899 enables us to focus all of our resources on advancing our core strategic HCV assets, which include drug candidates from the three major classes of direct-acting HCV antivirals."

"IDX899 may play a significant role in improving treatment options for people with HIV/AIDS," commented Zhi Hong, Senior Vice President of the Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD) at GSK. "A once-daily, lower-dose
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... A new analysis and infographic released ... Hepatitis C medications could range from hundreds of millions of ... Hepatitis C receive treatment through state programs. The analysis, which ... on public programs, comes at a time when state and ... Gilead Sciences, Harvoni and Sovaldi. ...
(Date:6/30/2015)...  Inari Medical, Inc. announced today that it has ... The financing was led by members of the board ... Venture Partners.  The round also included participation by several ... pleased to complete this financing with the support of ... who joined in February 2015 as President and Chief ...
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
Breaking Medicine Technology:New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: ... updated the progress of its Phase II,clinical ... cancer patients who are unable to tolerate ... trial for first-line,treatment of biliary cancer patients. ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Cached Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:6/30/2015)... ... ... Down is a reliable source for last minute tickets for The Rolling Stones at ... North America in conjunction with their 2015 “Zip Code Tour.” , The Stones have been ... their twenties. Some of the most beloved songs that this iconic group has performed ...
(Date:6/30/2015)... Minn. (PRWEB) , ... June 30, 2015 , ... The ... million in funding for 24 projects across the state. The projects improve community health ... range from $25,000 to $100,000 and many are renewable for a second year in ...
(Date:6/30/2015)... Monica, CA (PRWEB) , ... June 30, 2015 ... ... of its new YouTube video, “Fireside Convalescent Care Center.” The video informs community ... the video after continually seeing the need for those seeking care to be ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand Terrace Health ... Health Care Center.” Each year, Medicare ranks care centers around the country in ... for their needs. Grand Terrace prides itself on quality in each of Medicare’s ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... that they have been awarded the exclusive billing agreements with Jackson Radiology Associates ... billing services encompassing their proprietary suite of billing process software functionality called Experience ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Blue Cross and Blue Shield of Minnesota Foundation Awards $1.5 Million 2Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2
... has taken over as the Director General of Army's Medical ... Medical College, Nagpur he was commissioned into the Army Medical ... from Pune University in 1977, he completed training in Radiation ... MD from Bombay University. ,A pioneer in ...
... of the journal SLEEP finds that people with obstructive ... disease.// ,The study attributes the increased link ... a rising prevalence. Results suggest that OSA plays a ... hypertension. ,"There is abundant physiologic evidence ...
... fragrant, blooming trees and lush green grasses – and sneezing ... ,Hay fever, or seasonal allergic rhinitis, affects an ... and watery eyes, runny nose and a burning or itchy ... commonly caused by tree and grass pollens, and depends on ...
... green tea has long been touted for its healthful ... found// that a component of green tea, combined with ... spread of human prostate cancer. ,In the ... University of Wisconsin-Madison demonstrate that low doses of the ...
... study has proven false established medical practice that an antiretroviral ... safe to use// on its own in patients co-infected with ... cross-resistance to other antiviral drugs used to treat the AIDS ... different from any other that has been shown to be ...
... negative social reactions may increase the psychological effects of ... at Chicago study. ,The study, published in ... negative reactions that victims experience when seeking support could ... symptoms. ,The findings suggest further public education ...
Cached Medicine News:Health News:Sleep Well, Have a Healthy Heart ! 2Health News:Weather Forecasts Spring Pollen Allergy Severity 2Health News:Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer 2Health News:Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer 3Health News:Widely Used Hepatitis B Drug Spurs HIV Drug Resistance 2Health News:Widely Used Hepatitis B Drug Spurs HIV Drug Resistance 3Health News:Study Examines Negative Reactions to Sexual Assault Victims 2
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: